Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 13/20 | 0.55 |
| ▸ | PFKFB1 | P16118 | 12/20 | 0.55 |
| ▸ | PFKFB2 | O60825 | 9/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653293 | 0.82 | PFKFB3 (0.41) | PFKFB3PFKFB1PFKFB2PSMB8 | |
| SCHEMBL21653197 | 0.82 | RAB9A (0.55) | — | |
| SCHEMBL21653001 | 0.81 | PFKFB3 (0.40) | PFKFB3PFKFB1PFKFB2PSMB8 | |
| SCHEMBL21653300 | 0.81 | PTPN1 (0.54) | — | |
| SCHEMBL21652994 | 0.81 | PFKFB3 (0.44) | PFKFB3PFKFB1PFKFB2PSMB8KHK | |
| SCHEMBL21652996 | 0.80 | PFKFB3 (0.40) | PFKFB3PFKFB1PFKFB2PSMB8 | |
| SCHEMBL21652993 | 0.80 | PFKFB3 (0.39) | PFKFB3PFKFB1PFKFB2PSMB8 | |
| SCHEMBL21652984 | 0.78 | ALOX15 (0.48) | ULK1KHK | |
| SCHEMBL21652982 | 0.75 | ALDH1A1 (0.46) | — | |
| SCHEMBL19234761 | 0.73 | SCN3A (0.52) | PFKFB3PFKFB1PFKFB2PSMB8ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |